LifeSci Capital analyst Francois Brisebois initiated coverage of Compass Pathways (CMPS) with an Outperform rating and $15 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Psychedelic: Analyst raises Compass, Definium, GH Research price targets
- Compass Pathways price target raised to $21 from $16 at RBC Capital
- 3 ‘Strong Buy’ Stocks to Buy Today,1/9/2026, According to Top Analysts
- De-Risked Clinical Profile and Growing Commercial Infrastructure Support Buy Rating on COMPASS Pathways’ COMP360
- Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial